Crystalys raises $130 million to advance dotinurad through global Phase 3 gout trials
- nuaxia
- 1 day ago
- 2 min read
The Series B financing gives Crystalys additional capital to progress its late-stage clinical programme and prepare dotinurad for potential commercialisation.
Crystalys Therapeutics has closed an oversubscribed $130 million Series B financing led by Frazier Life Sciences to support the global late-stage development and commercialisation preparation of dotinurad for gout.
The investment extends support for two registration-directed Phase 3 trials and a Phase 2 study as the company works towards further clinical, regulatory and commercial-readiness milestones.
Field | Content |
Alert Type | Deal |
Companies | Crystalys Therapeutics; financing led by Frazier Life Sciences, with participation from Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management, Trails Edge Capital Partners, Pivotal bioVenture Partners, KCap Biotechnology Fund and existing investors. |
Deal Type | Series B financing |
Asset or Company | Crystalys Therapeutics and its lead candidate, dotinurad |
Therapy Area(s) | Rheumatology; gout |
Technology or Modality | Once-daily oral URAT1 inhibitor |
Deal Value | $130 million in closed Series B financing. |
Development Stage | Phase 3, with two registration-directed studies underway; an additional Phase 2 study is also ongoing. |
Geography | Global clinical development and commercialisation preparation |
What Happened | Crystalys closed an oversubscribed $130 million Series B round led by Frazier Life Sciences. The proceeds will support the RUBY and TOPAZ Phase 3 trials, the Phase 2 AMETHYST study, commercialisation preparation and the company’s operational runway through anticipated clinical and regulatory milestones. |
Why It Matters | The financing provides Crystalys with additional resources to progress dotinurad across a broad gout-development programme while preparing the company for potential regulatory submissions and commercialisation. It also supports continued development of a possible second-line option for patients inadequately served by existing urate-lowering treatments. |
Supporting Context | Dotinurad is already approved in Japan, China, the Philippines, Taiwan and Thailand. Crystalys is developing it as a potential second-line therapy intended to reduce uric acid, gout flares and tophi. |
Key Takeaway | The $130 million financing gives Crystalys further runway to move dotinurad through late-stage development and towards commercial readiness. |
What to Watch | Results from the RUBY, TOPAZ and AMETHYST studies and any subsequent clinical, regulatory or commercialisation milestones. |
Primary Source | |
Relevant Date | 22 July 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments